<DOC>
	<DOCNO>NCT00907777</DOCNO>
	<brief_summary>The aim study ass immune response , safety reactogenicity follow administration additional dose pneumococcal conjugate vaccine approximately 4 year age child previously vaccinate 3 primary dos GSK 1024850A Prevenar™ vaccine within first 6 month life booster dose plain polysaccharide pneumococcal ( Pneumovax 23™ ) vaccine 11-14 month age . Antibody persistence also assess approximately 4 year age child previously vaccinate 3 dos either GSK 1024850A Prevenar™ vaccine follow booster dose Pneumovax 23™ . This protocol post deal objective &amp; outcome measure extension phase year 4 . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT 00307541 ) . The objective &amp; outcome measure booster phase present separate protocol posting ( NCT 00333450 ) .</brief_summary>
	<brief_title>Vaccination With GSK 1024850A Children Primed With GSK 1024850A &amp; Boosted With Pneumovax 23™</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female , include , 4650 month age time vaccination . Subjects investigator believe parents/guardians comply requirement protocol . Subjects previously participate study NCT00333450 centre 2 subject receive booster dose Pneumovax 23™ . Written inform consent obtain parents/guardians subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine ( ) within 30 day precede vaccination , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior vaccination . Planned administration/ administration vaccine foreseen study protocol period start one month study vaccination entire study period . Administration pneumococcal vaccine since end study NCT00333450 . Administration immunoglobulins and/or blood product less 3 month prior vaccination plan use study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical History neurologic disorder seizures Anaphylactic reaction follow previous administration vaccine history reaction allergic disease likely exacerbate component vaccine . History hypotonichyporesponsive episode previous vaccination . Major congenital defect serious chronic illness . History invasive pneumococcal disease . Acute disease time vaccination Rectal temperature &gt; = 38.0°C oral/axillary/tympanic temperature &gt; = 37.5°C . A temperature great equal cutoff warrant deferral vaccination pending recovery subject .</criteria>
	<gender>All</gender>
	<minimum_age>46 Months</minimum_age>
	<maximum_age>50 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Haemophilus influenzae</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>safety</keyword>
	<keyword>Pneumococcal conjugate vaccine</keyword>
	<keyword>immunogenicity</keyword>
</DOC>